

PUBLICATIONS:

Spirtos NM, Enserro D, Homesley HD, Gibbons SK, Cella D, Morris RT, DeGeest K, Lee RB, Miller DS. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) Study. *Gynecol Oncol*. 2019 April 30. PMID: 31053405

Fletcher NM, Harper AK, Memaj I, Fan R, Morris RT, Saed GM. Molecular basis supporting the association of talcum powder use with increased risk of ovarian cancer. *Reprod Sci*. 2019 Feb 28. PMID: 30819054

Von Gruenigen VE, Huang HQ, Cella D, Zevon M, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, Wenzel L. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol*. 2018 Jul;150(1):119-126. PMID: 29778506

Jeelani R, Chatzicharalampous C, Kohan-Ghadr HR, Awonuga A, Joshi N, Morris RT, Abu-Soud HM. Acrolein, a commonly found environmental toxin, causes oocyte mitochondrial dysfunction and negatively affects embryo development. *Free Radic Res*. 2018 Jun 11:1-191. PMID: 29886754

Jeelani R, Maitra D, Chatzicharalampous C, Najeemuddin S, Morris RT, Abu-Soud HM. Melatonin prevents hypochlorous acid-mediated cyanocobalamin destruction and cyanogen chloride generation. *J Pineal Res*. 2018 Apr;64(3). PMID:29247550

Saed GM, Fletcher NM, Diamond MP, Morris RT, Gomez-Lopez N, Memaj I. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target. *Gynecol Oncol*. 2018 Mar;148(3):567-575. PMID: 29329880

Aldhaheri SR, Jeelani R, Kohan-Ghadr HR, Khan SN, Mikhael S, Washington C, Morris RT, Abu-Soud HM. Dimercapto-1-propanesulfonic acid (DMPS) induces metaphase II mouse oocyte deterioration. *Free Radic Biol Med*. 2017 Nov;112:445-451. PMID: 28844937

Abdulfatah E, Sakr S, Thomas S, Al-Wahab Z, Mutch DG, Dowdy S, Bandyopadhyay S, Munkarah A, Elshaikh M, Morris R, Ali-Fehmi R. Clear cell carcinoma of the endometrium: evaluation of prognostic parameters in a multi-institutional cohort of 165 cases. *Int J Gynecol Cancer*. 2017 Oct;27(8):1714-1721. PMID:28945214

Mahdi Z, Abdulfatah E, Pardeshi V, Hassan O, Schultz D, Morris R, Cote ML, Elshaikh MA, Bandyopadhyay S, Ali-Fehmi R. The impact of androgen receptor expression on endometrial carcinoma recurrence and survival. *Int J Gynecol Pathol*. 2017 Sep;36(5):405-411. PMID: 28277313

Winer I, Patel D, Dalton V, Johnston C, Quint EH, Zochowski M, Munkarah A, Morris R, Haefner H. Involvement and comfort of gynecologic oncologists in the treatment of pediatric, adolescent, and young adult patients with gynecologic malignancies. *Int J Gynaecol Obstet*. 2017 Aug;138(2):177-182. PMID:28485838

Aldhaheri SR, Jeelani R, Kohan-Ghadr HR, Khan SN, Mikhael S, Washington C, Morris RT, Abu-Soud HM. Dimercapto-1-propanesulfonic acid (DMPS) induces metaphase II mouse oocyte deterioration. *Free Radic Biol Med*. 2017 Aug 24;112:445-451. PMID: 28844937

Sakr S, Abdulfatah E, Thomas S, Al-Wahab Z, Beydoun R, Morris R, Al-Fehmi R, Bandyopadhyay S. Granulosa cell tumors: novel predictors of recurrence in early-stage patients. *Int J Gynecol Pathol.* 2017 May;36(3):240-252. PMID: 28727617

Hou Z, Gattoc L, O'Connor C, Yang S, Wallace-Povirk A, George C, Orr S, Polin L, White K, Kushner J, Morris RT, Gangjee A, Matherly LH. Dual targeting of epithelial ovarian cancer via folate receptor α and the Proton-Coupled Folate Transporter with 6-substituted pyrrolo[2.3-d]pyrimidine antifolates. *Mol Cancer Ther.* 2017 May;16(5):819-830. PMID: 28138029

Jeelani R, Jahanbakhsh S, Kohan-Ghadr HR, Thakur M, Khan S, Aldhaheri SR, Yang Z, Andreana P, Morris R, Abu-Soud HM. Mesna (2-mercaptoethane sodium sulfonate) functions as a regulator of myeloperoxidase. *Free Radic Biol Med.* 2017 May 25;110:4-62. PMID: 28552694

Jeelani R, Khan SN, Shaeib F, Kohan-Ghadr HR, Aldhaheri SR, Najafi T, Thakur M, Thakur M, Morris R, Abu-Soud HM. Cyclophosphamide and acrolein induced oxidative stress leading to deterioration of metaphase II mouse oocyte quality. *Free Radic Biol Med.* 2017 May 9;110:11-18. PMID: 28499912

Fletcher NM, Belotte J, Saed MG, Memaj I, Diamond MP, Morris RT, Saed GM. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer. *Free Radic Biol Med.* 2017 Jan;102:122-132.

Rose PG, Java JJ, Morgan MA, Alvarez-Secord A, Kesterson JP, Stehman FB, Warshal DP, Creasman WT, Hanjani P, Morris RT, Copeland LJ. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol.* 2016 Dec;143(3):511-515. doi: 10.1016/j.ygyno.2016.09.005.

Zaki M, Dominello M, Morris R, Miller S. Factors predictive of protracted course of radiation therapy in patients treated with definitive chemoradiation for cervical cancer. *Cureus.* 2016 Apr 4;8(4):e558. Doi: 10.7759/cureus.558.

Winer I, Alvarado-Cabrero I, Hassan O, Ahmed QF, Alesh B, Bandyopadhyay S, Thomas S, Albayrak S, Talukdar S, Al-Wahab Z, Elshaikh MA, Munkarah A, Morris R, Ali-Fehmi R. The prognostic significance of histologic type in early stage cervical cancer – A multi-institutional study. *Gynecol Oncol.* 2015 Jun;137(3):474-8. doi: 10.1016/j.ygyno.2015.02.005.

Al-Wahab Z, Mert I, Tebbe C, Chhina J, Hijaz M, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction. *Oncotarget.* 2015 May 10;6(13):10908-23.

Mahdi H, Rose PG, El-Shaikh MA, Munkarah A, Isrow D, Singh S, Waggoner S, Ali-Fehmi R, Morris RT, Harding J, DeBenardo R. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study. *Gynecol Oncol.* 2015 May;136(3):529-33. doi:10.1016/j.ygyno.2014.12.034.

Mahdi H, Elshaikh MA, DeBenardo R, Munkarah A, Isrow D, Singh S, Waggoner S, Ali-Fehmi R, Morris R, Harding J, Moslemi-Kebria M. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. *Gynecol Oncol.* 2015 May;137(2):239-44. doi:10.1016/j.ygyno.2015.01.544.

Tainsky MA, Morris RT. Preface. *Cancer Metastasis Rev.* 2015 Mar;34(1):3. doi:10.1007/s10555-014-9548-7.

Winer I, Ahmed QF, Mert I, Bandyopadhyay S, Cote M, Munkarah AR, Hussein Y, Al-Wahab Z, Elshaikh MA, Alesh B, Schultz DS, Mahdi H, Nucci MR, Van de Vijver KK, Morris RT, Oliva E, Ali-Fehmi. Recurrence patterns and survival endpoints in women with Stage II uterine endometrioid carcinoma: a multi-institution study. *Gynecol Oncol.* 2015, Feb; 136(2):235-9.

Ahmed QF, Gattoc L, Al-Wahab Z, Abdulfatah E, Ruterbusch JJ, Cote M, Bandyopadhyay S, Morris RT, Ali-Fehmi R. Vanishing endometrial cancer in hysterectomy specimens: A myth or a Fact. *Am J Surg Pathol.* 2015 Feb;39(2):221-6. doi: 10.1097/PAS.0000000000000361.

Belotte J, Fletcher NM, Alexis M, Morris RT, Munkarah AR, Diamond MP, Saed GM. Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer. *Reprod Sci.* 2015 Jan;22(1):38-46. doi.10.1177/1933719114542021.

Winer I, Ahmed QF, Mert I, Bandyopadhyay S, Cote M, Munkarah AR, Hussein Y, Al-Wahab Z, Elshaikh MA, Alesh B, Schultz DS, Mahdi H, Nucci MR, Van de Vijver KK, Morris RT, Oliva E, Ali-Fehmi R. Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence? *Int J Gynecol Pathol.* 2015 Jan;34(1):47-56. doi:10.1097/PGP.0000000000000113.

Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Frissius-Quecke H, Krasner CN. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A Phase II Study. *Int J Gynecol Cancer.* 2014 Nov;24(9):1583-9. doi:10.1097/IGC.0000000000000286.

Al-Wahab Z, Tebbe C, Chhina J, Dar SA, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R. Dietary energy balance modulates ovarian cancer progression and metastasis. *Oncotarget.* 2014 Aug 15;5(15):6063-75.

Garg G, Yee C, Schwartz K, Mutch DG, Morris RT, Powell MA. Patterns of care, predictors, and outcomes of chemotherapy in elderly woman with early-stage uterine carcinosarcoma: A population-based analysis. *Gynecol Oncol.* 2014 May;133(2):242-9. doi: 10.1016/j.gyno.2014.02.021.

Cote ML, Ruterbusch JJ, Ahmed Q, Bandyopadhyay S, Alesh-B, Abdulfatah E, Seward S, Morris R, Ali-Fehmi R, Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes? *Gynecol Oncol.* 2014 Apr;133(1):38-42.

Morris RT, Joyrich RN, Naumann RW, Shah NP, Maurer AH, Strauss HW, Uszler JM, Symanowski JT, Ellis PR, Harb WA. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99m Tc-etarforatide). *Ann Oncol.* 2014 Apr;25(4):852-8. doi:10.1093/annonc.mdu024.

Al-Wahab ZR, Kumar S, Mutch DG, Dowdy SC, Hensley SA, Wang Y, Mahdi H, Ali-Fehmi R, Morris RT, Elshaikh M, Munkarah, AR. Racial disparities in uterine clear cell carcinoma: a multi-institution study. *Int J Gynecol Cancer.* 2014 Mar;24(3):541-8. doi:10.1097/IGC.0000000000000068.

Ahmed Q, Hussein Y, Hayek K, Bandyopadhyay S, Semaan A, Abdul-Karim F, Al-Wahab Z, Munkarah AR, Elshaikh MA, Alosch B, Nucci MR, Van de Vijver KK, Morris RT, Oliva E, Ali-Fehmi R. Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis. *Gynecol Oncol.* 2014 Feb;132(2):372-6. doi: 10.1016/j.ygyno.2013.11.011. Epub 2013 Nov 19.

Dominello MM, Paximadis P, Kaufman I, Munns S, Dyson G, Konski A, Morris R, Miller S. Predictor of outcome in early-stage papillary serous and clear cell endometrial cancer. *Intl J Rad Onc Bio Phys.* 2013 Oct. 1:87(2)s421-422. doi: 10.1016/j.jrobp.2013.06.1108.

Munns S, Semaan A, Seward S, Munkarah A, Paximadis P, Miller S, Ali R, Morris R. Treatment-related outcomes in patients with Stage III-IV endometrial cancer treated with chemotherapy with or without the addition of radiation therapy. *J Gyn Onc.* 2013 July: 130(1):e76 doi: 10.1016/j.ygyno.2013.04.241.

Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, Kumar S, Cameron D, Sethi S, Ali-Fehmi R, Morris R, Bouwman DL, Munkarah AR, Weaver DW, Gruber SA, Batchu RB EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53. *Cancer Lett* 2013 Aug 9; 336(1):53-60. Epub 2013 Apr 18.

Mert I, Semaan A, Winer I, Morris RT, Ali-Fehmi R. Vulvar/vaginal melanoma: an updated surveillance epidemiology and end results database review, comparison with cutaneous melanoma and significance of racial disparities. *Int J Gynecol Cancer.* 2013 Jul;23(6):1118-25. Doi: 10.1097/IGC.0b013e3182980ffb.

Kumar S, Al-Wahab Z, Sarangi S, Woelk J, Morris R, Munkarah A, Dowdy SC, Mariani A, Cliby W, Risk of postoperative venous thromboembolism after minimally invasive surgery for endometrial and cervical cancer is low: A multi-institutional study. *Gynecol Cancer.* 2013 Jul;130(1):207-12.

Semaan A, Mert I, Munkarah AR, Bandyopadhyay S, Mahdi HS, Winer IS, Nucci MR, Hussein Y, Quershi F, Hayek K, Tabassum F, Alosch B, Schultz DS, Cote ML, Vijver KK, Morris RT, Oliva E, Ali-Fehmi R. Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study. *Int J Gynecol Pathol.* 2013 Mar;32(2):181-7. doi: 10.1097/PGP.0b013e318273fc55. PubMed PMID: 23370657.

Winer I, Mahdi H, Bandyopadhyay S, Semaan A, Van de Vijver KK, Nucci MR, Abdul-Karim F, Hussein Y, Qureshi F, Hayek K, Alosch B, Schulz D, Cote M, Munkarah A, Morris R, Oliva E, Ali-Fehmi R. Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study. *Gynecol Oncol.* 2013 Feb;128(2):316-21. doi: 10.1016/j.ygyno.2012.10.027. Epub 2012 Nov 5. PubMed PMID: 23138135.

Kaplun L, Fridman AL, Chen W, Levin NK, Ahsan S, Petrucelli N, Barrick JL, Gold R, Land S, Simon MS, Morris RT, Munkarah AR, Tainsky MA. Variants in the Signaling Protein TSAd are Associated with Susceptibility to Ovarian Cancer in BRCA1/2 Negative High Risk Families. *Biomark Insights.* 2012;7:151-7. doi: 10.4137/BMI.S10815. Epub 2012 Dec 12. PubMed PMID: 23300341; PubMed Central PMCID: PMC3528110.

Semaan A, Ali-Fehmi R, Munkarah AR, Bandyopadhyay S, Morris RT, Rizk S, Mert I, Ruterbusch JJ, Cote ML. Clinical/pathologic features and patient outcome in early onset endometrial carcinoma: a population based analysis and an institutional perspective from the Detroit metropolitan area, Michigan. *Gynecol Oncol.* 2012 Feb;124(2):265-9. doi: 10.1016/j.ygyno.2011.09.027. Epub 2011 Nov 1.

Seward S, Ali-Fehmi R, Munkarah AR, Semaan A, Al-Wahab Z, Elshaikh MA, Cote ML, Morris RT, Bandyopadhyay S. Outcomes of Patients With Uterine Serous Carcinoma Using the Revised FIGO Staging System. *International Journal of Gynecologic Cancer*. *Int J Gynecol Cancer*. 2012 Mar;22(3):452-6.

Chatterjee M, Dyson G, Levin K, Shah JP, Morris R, Munkarah A, Tainsky MA. Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence. *Cancer Biomarkers* 2012 Jan 1;11(2):59-73.

Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Munkarah AR, Weaver DW, Gruber SA, Batchu RB. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf⁻¹/cip⁻¹). *Pharm Res*. 2011 Dec;28(12):3079-90. doi: 10.1007/s11095-011-0547-x. Epub 2011 Aug 5. PubMed PMID: 21818714.

Garg G, Morris RT, Solomon L, Toy EP, Kruger M, Clary K, Munkarah A, Wright JD. Evaluating the significance of location of lymph node metastasis and extranodal disease in women with stage IIIc endometrial cancer. *Gynecol Oncol*. 2011 Nov;123(2):208-13. Epub 2011 Aug 6.

Guan H, Semaan A, Bandyopadhyay S, Arabi H, Feng J, Fathallah L, Pansare V, Qazi A, Abdul-Karim F, Morris RT, Munkarah AR, Ali-Fehmi R. Prognosis and reproducibility of new and existing binary grading systems for endometrial carcinoma compared to FIGO grading in hysterectomy specimens. *Int J Gynecol Cancer*. 2011 May;21(4):654-60. doi: 10.1097/IGC.0b013e31821454f1. PubMed PMID:21543931.

Vay A, Kumar S, Seward S, Semaan A, Schiffer CA, Munkarah AR, Morris RT. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: An epidemiological analysis. *Gynecol Oncol*. 2011 Aug 18.

Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, Tamimi H, Morris RT, Munkarah AR. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. *Br J Cancer*. 2011 Aug 9;105(4):493-7. Epub 2011 Jul 19.

Garg G, Shah JP, Toy EP, Christensen C, Deppe G, Asaad R, Morris RT. Stage IIA1 Versus Stage IIA2 Cervical Cancer: Does the New Staging Criteria Predict Survival? *Int J Gynecol Cancer*. 2011 May;21(4):711-6.

Mahdi H, Kumar S, Hanna RK, Munkarah AR, Lockhart D, Morris RT, Tamimi H, Swensen RE, Doherty M. Disparities in treatment and survival between African American and White women with vaginal cancer. *Gynecol Oncol*. 2011 Jul;122(1):38-41. Epub 2011 Apr 15.

Al-Wahab Z, Ali-Fehmi R, Cote ML, Elshaikh MA, Ibrahim DR, Semaan A, Schultz D, Morris RT, Munkarah AR. The impact of race on survival in uterine serous carcinoma a hospital-based study. *Gynecol Oncol*. 2011 Jun 1;121(3):577-80. Epub 2011 Mar 4.

Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Ali-Fehmi R. Expression of GLUT-1 in epithelial ovarian carcinoma: Correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. *Gynecol Oncol*. 2011 Apr;121(1):181-6. Epub 2010 Dec 16.

Kumar S, Munkarah A, Arabi H, Bandyopadhyay S, Semaan A, Hayek K, Garg G, Morris R, Ali-Fehmi R. Prognostic analysis of ovarian cancer associated with endometriosis. *Am J Obstet Gynecol*. 2011 Jan;204(1):63.e1-7. doi:10.1016/j.ajog.2010.08.017. Epub 2010 Nov 11. PubMed PMID: 21074136.

Kumar S, Bandyopadhyay S, Semaan A, Shah JP, Mahdi H, Morris R, Munkarah A, Ali-Fehmi R. The role of frozen section in surgical staging of low risk endometrial cancer. *PLoS One*. 2011;6(9):e21912. Epub 2011 Sep 1.

Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, Tamimi H, Morris RT, Munkarah AR. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. *Br J Cancer*. 2011 Aug 9;105(4):493-7. Epub 2011 Jul 19.

Garg G, Shah JP, Toy EP, Field JB, Bryant CS, Liu JR, Morris RT. Intra-operative detection of nodal metastasis in early stage cervical cancer: a survey of the practice patterns of SGO members. *Gynecol Oncol*. 2011 Apr;121(1):143-7. Epub 2011 Jan 26.

Bryant CS, Kumar S, Spannuth W, Shah JP, Munkarah AR, Deppe G, Alvarez RD, Morris RT. Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer. *Arch Gynecol Obstet*. 2011 Feb;283(2):361-7. Epub 2010 Apr 11.

Ali-Fehmi R, Semaan A, Sethi S, Arabi H, Bandyopadhyay S, Hussein YR, Diamond MP, Saed G, Morris RT, Munkarah AR. Molecular typing of epithelial ovarian carcinomas using inflammatory markers. *Cancer*. 2011 Jan 15;117(2):301-9. Epub 2010 Sep 3.

Garg G, Shah JP, Liu JR, Bryant CS, Kumar S, Munkarah A, Morris RT. Validation of tumor size as staging variable in the revised international Federation of gynecology and obstetrics stage I leiomyosarcoma: a population-based study. *Int J Gynecol Cancer*. 2010 Oct;20(7):1201-6.

Bryant CS, Munkarah AR, Kumar S, Batchu RB, Shah JP, Berman J, Morris RT, Jiang ZL, Saed GM. Reduction of hypoxia-induced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression. *Arch Gynecol Obstet*. 2010 Dec;282(6):677-83. Epub 2010 Feb 7.

Morris RT, Monk BJ. Ovarian cancer: relevant therapy, not timing, is paramount. *Lancet*. 2010 Oct 2;376(9747):1120-2.

Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. *Int J Gynecol Cancer*. 2010 Jul;20(5):888-94. doi:10.1111/IGC.0b013e3181dc8292. PubMed PMID: 20606539.

De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. *J Clin Oncol*. 2010 Jan 1;28(1):149-53. Epub 2009 Nov 16.

Bryant CS, Kumar S, Shah JP, Mahdi M, Ali-Fehmi R, Munkarah AD, Deppe G, Morris RT. Racial disparities in survival among patients with germ cell tumors of the ovary United States. *Gynecol Oncol*. 2009 Sep;114(3):437-41. Epub 2009 Jun 26.

Kumar S, Shah JP, Bryant CS, Imudia AN, Ali-Fehmi R, Malone JM Jr, Morris RT. Prognostic significance of keratinization in squamous cell cancer of uterine cervix: a population based study. Arch Gynecol Obstet. 2009 Jul;280(1):25-32. Epub 2008 Nov 29.

Kumar S, Shah JP, Bryant CS, Awonuga AO, Imudia AN, Ruterbusch JJ, Cote ML, Ali-Fehmi R, Morris RT, Malone JM Jr. Second neoplasms in survivors of endometrial cancer: Impact of radiation therapy. Gynecol Oncol. 2009 May; 113(2):233-9. Epub 2009 Feb 26.

Kumar S, Shah JP, Bryant CS, Imudia AN, Morris RT, Malone JM Jr. A comparison of younger vs older women with vulvar cancer in the United States. Am J Obstet Gynecol. 2009 May;2009 (5):e52-5. Epub 2008 Dec 25.

Homesley HD, Filaci V, Gibbons K, Long HJ, Spirtos NM, Morris RT, DeGeest K, Lee RB. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel. Gynecol Oncol. 2009 Mar; 112(3):543-52. Epub 2008 Dec 23.

Kumar S, Morris RT, Malone JM Jr. Relative mortality in the women over 60 years of age with cervical cancer. Gynecol Oncol. 2009 Feb;112(2):437; author reply 437-8. Epub 2008 Jun 9.

Bryant CS, Shah JP, Triest JA, Schimp VL and Morris RT. Bladder erosion by an intraperitoneal chemotherapy catheter resulting in catheter protrusion through the external urethral meatus. Gynecol Oncol. 2008 Dec;111(3):552-4. Epub 2008 Mar 4.

Kumar S, Shah JP, Bryant CS, Seward S, Al-Fehmi R, Morris RT, Malone Jr. JM. Radiation-Associated Endometrial Cancer. Am J of Obstet and Gynecol. Fed; Vol 113, No. 2. 2009.

Shah JP, Kumar S, Bryant CS, Ali-Fehmi R, Malone JM Jr., Deppe G, Morris RT. A population-based analysis of 788 cases of yolk sac tumors: A comparison of males and females. Int J Cancer. 2008 Dec 1; 123 (11):2671-5.

Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT, Sarkar FH. Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB. J Ovarian Res. 2008 Nov 24;1(1):9.

Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malone JM, Morris RT. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. ACOG. November 2008. Vol (112), No. 5.

Kumar S, Shah JP, Bryant CS, Imudia AN, Cote ML, Ali-Fehmi R, Malone JM Jr., Morris RT. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol. June 2008 110: 125-132.

Morris RT, Alvarez RD, Andrews S, Malone J, Bryant CS, Heilbrun LK, Schimp V, Munkarah AR. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol. 2008. 109. 346-352.

Pansare V, Munkarah AR, Schimp V, Haitham Arabi M, Saed GM, Morris RT, Ali-Fehmi R. Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod Pathol.20(1):35-43.2007.

Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Femi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah AR, Morris RT, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen clone and detection on arrays. *Cancer Res* 66(2):1181-90, 2006.

Schimp VL, Ali-Fehmi R, Solomon LA, Hammoud A, Pansare V, Morris RT, Munkarah AR. The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level? *Gynecol Oncol*. 102(3):440-6, 2006.

Solomon LA, Munkarah AR, Schimp VL, Morris RT, Nassar H, Ali-Fehmi R. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. *Gynecol Oncol* 101(3):385-389, 2006.

Khalifeh I, Munkarah AR, Schimp VL, Malone JM, Morris RT, Lawrence WD, Ali-Fehmi R. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma. *Int J Gynecol Pathol.*; 24(3):228-34 2005.

Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp VL, Malone JJ, Munkarah AR. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. *Am J of Obstet Gynecol*. 192, 819-25 2005.

Bhoola SM, Coleman RL, Herzog T, Morris RT, Bryant C, Estes JM, Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. *Gynecol Oncol*. 95(3):564-9 2004.

Khalifeh I, Munkarah AR, Lonardo F, Malone JM, Morris RT, Lawrence WD, Ali-Fehmi R, Expression of Cox-2, CD34, Bel-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. *Int J Gynecol Pathol*. 23(2):162-9 2004.

Saad A, Lo S, Han I, Keole S, Lee CP, Tekyi-Mensah S, Munkarah AR, Malone JM, Morris RT, Deppe G, Radiation therapy with or without chemotherapy for cervical cancer with periaortic lymph node metastasis. *Am J Clin Oncol*. Jun;27(3):256-63, 2004.

Morris RT, Munkarah AR, Alternative Dosing Regimens for Topotecan in Relapsed Ovarian Cancer. *Advances in Ovarian Cancer*, Vol 2. No.1, 7-9 2003.

Schimp VL, Munkarah AR, Morris RT, Deppe G, Jr. Malone JJ, Upper Extremity Deep Vein Thrombosis Associated with Indwelling Peripheral Venous Catheters in Gynecology Oncology Patients. *Gynecol Oncol* May;89 (2):301-5, 2003.

Ali-Femi R, Che M, Khalifeh I, Malone JM, Morris RT, Lawrence WD, Munkarah AR, The effect of cyclooxygenase-2 expression on tumor vascularity in advance stage ovarian serous carcinoma. *Cancer* 98(7):1423-9 2003.

Morris RT, Weekly Topotecan in the management of ovarian cancer. *Gynecol Oncol* 90 (3Pt2):S34-8, 2003.

Munkarah AR, Genhai Z, Morris RT, Baker VV, Deppe G, Diamond M, Saed GM. Inhibition of Paclitaxel Induced Apoptosis by the Specific COX-2 Inhibitor, NS398, in epithelial ovarian cancer cells. *Gynecol Oncol* 88:429-33, 2003.

Morris RT, Alternative Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer; Phase II Trial of Weekly Topotecan in Patients with Potentially Platinum-Sensitive Relapsed Ovarian and Peritoneal Cancer. Guest Editor; Therapeutic Focus Review and Expert Commentary, Vol 2: 3-6, 2003.

Munkarah AR, Morris RT, Bauman P, Deppe G, Jr. Malone JJ, Diamond MP, Saed GM. Effects of Prostaglandin E(2) on Proliferation and Apoptosis of Epithelial Ovarian Cancer Cells. J Soc Gynecol Investig. 9(3):168-73 2002.

Munkarah AR, Levenback C, Wolf JK, Bodurka-Bevers D, Tortolero-Luna G, Morris RT, Gershenson D. Secondary cytoreductive surgery for localized Intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol. 81:237-241, 2001.

Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Wharton JT. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 95:541-547, 2000.

Doss BJ, Jacques SM, Qureshi F, Chang CH, Christensen CW, Morris RT, Lawrence WD. Immature teratomas of the genital tract in older women. Gynecol Oncol. 73:433-438, 1999.

Gregoire L, Munkarah AR, Rabah R, Morris RT, Lancaster WD. Organotypic culture of human ovarian surface epithelial cells: a potential model for ovarian carcinogenesis. In Vitro Cell Dev Biol 34:636-639, 1998.